Literature DB >> 12237155

Pharmacotherapy for Alzheimer's disease: progress and prospects.

Alan M Palmer1.   

Abstract

The number of people with Alzheimer's disease has never been greater and is set to increase substantially in the decades ahead as the proportion of the population aged 65 years or more rises sharply. There is, therefore, a substantial and increasing need for effective pharmacotherapy. Increased understanding of disease pathophysiology has led to palliative treatments for both cognitive and non-cognitive changes in behaviour. This, together with the prospect of drugs that slow or perhaps even halt the course of the disease, raises hope that this devastating disorder will soon be more amenable to pharmacotherapy with new drugs that either ameliorate specific symptoms or alter the course of the disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12237155     DOI: 10.1016/s0165-6147(02)02056-4

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  17 in total

Review 1.  Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.

Authors:  Mohammad S Alavijeh; Mansoor Chishty; M Zeeshan Qaiser; Alan M Palmer
Journal:  NeuroRx       Date:  2005-10

2.  Cognitive performance of healthy young rats following chronic donepezil administration.

Authors:  Debora Cutuli; Francesca Foti; Laura Mandolesi; Paola De Bartolo; Francesca Gelfo; Francesca Federico; Laura Petrosini
Journal:  Psychopharmacology (Berl)       Date:  2008-02-29       Impact factor: 4.530

3.  Escitalopram Ameliorates Forskolin-Induced Tau Hyperphosphorylation in HEK239/tau441 Cells.

Authors:  Qing-Guo Ren; Yan-Juan Wang; Wei-Gang Gong; Qi-Da Zhou; Lin Xu; Zhi-Jun Zhang
Journal:  J Mol Neurosci       Date:  2015-02-17       Impact factor: 3.444

Review 4.  Alcohol drinking exacerbates neural and behavioral pathology in the 3xTg-AD mouse model of Alzheimer's disease.

Authors:  Jessica L Hoffman; Sara Faccidomo; Michelle Kim; Seth M Taylor; Abigail E Agoglia; Ashley M May; Evan N Smith; L C Wong; Clyde W Hodge
Journal:  Int Rev Neurobiol       Date:  2019-10-23       Impact factor: 3.230

5.  Cilostazol prevents amyloid β peptide(25-35)-induced memory impairment and oxidative stress in mice.

Authors:  Masayuki Hiramatsu; Osanao Takiguchi; Aki Nishiyama; Hiromasa Mori
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

6.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

Review 7.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

8.  Highly enantioselective borane reduction of heteroaryl and heterocyclic ketoxime ethers catalyzed by novel spiroborate ester derived from diphenylvalinol: application to the synthesis of nicotine analogues.

Authors:  Kun Huang; Francisco G Merced; Margarita Ortiz-Marciales; Héctor J Meléndez; Wildeliz Correa; Melvin De Jesús
Journal:  J Org Chem       Date:  2008-05-01       Impact factor: 4.354

9.  Network dynamics predict improvement in working memory performance following donepezil administration in healthy young adults.

Authors:  A Reches; I Laufer; K Ziv; G Cukierman; K McEvoy; M Ettinger; R T Knight; A Gazzaley; A B Geva
Journal:  Neuroimage       Date:  2013-11-21       Impact factor: 6.556

10.  Donepezil modulates nicotinic receptors of substantia nigra dopaminergic neurones.

Authors:  Silvia Di Angelantonio; Giorgio Bernardi; Nicola B Mercuri
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.